Moderator: Ulrika Mundt-Petersen
Wednesday 15, September 2021
|1830-1900||Wednesday Dinner: Pre-Dinner Talk:|
|Translation of neuropharamacology and nonmotor symptoms from animals to humans: where did we go wrong?|
|Chair: Ulrika Mundt-Petersen|
|Peter Jenner (England)|
Thursday 16, September, 2021
|0800 - 0810||Opening of the meeting|
|Dean of the Lund Faculty of Medicine/ Ray Chaudhuri/Per Odin|
|0810 - 0955||Session 1: Non-motor symptoms in prodromal phases of Parkinson´s disease|
|Chair: Håkan Widner|
|RBD and Hyposmia: can they help to select patients with prodromal alpha-Synucleinopathy (i.e. PD) for future neuroprotective trials ?
Wolfgang Oertel (Germany, web)
|Prodromal biomarkers: above and below the neck.
Per Borghammer (Denmark)
|Prodromal NMS in Parkinson’s and implications for clinical trials.
Daniela Berg (Germany)
|0955 - 1025||
|1025 - 1055||
Industry symposium: Bial: COMT inhibitors and non-motor symptoms in fluctuating PD: what do we know and where are we heading?
|1055 - 1310||Session 2: Non-motor symptoms in early and late stages of Parkinsonism
Chair: Pablo Martinez-Martin, Espen Dietrichs
|Early Motor Parkinson’s: nonmotor implications.
Alastair Noyce (UK)
|Late Parkinson’s : the nonmotor journey:
Anette Schrag (UK)
|In life biomarkers in Parkinson’s and NMS:
Oskar Hansson (Sweden)
Non-motor Symptoms in atypical PD:
|1310 - 1410||Lunch|
|1410 - 1515||HotSpots and nonmotor Parkinson’s
(10 min research hot spot presentations)
Chair : Gesine Paul-Visse, Per Svenningsson
Anna Sauerbier (Germany)
|DBS non-motor effects: time to be precise:
Haidar Dafsari (Germany)
|Pain and sensory testing:
|AI, digitisation and NMS:
Daniel van Wamelen (UK)
|NMS and profession and workforce:
Jonathan Timpka (Sweden)
|1515 - 1545||Coffee|
|1545 - 1830||Session 3: Treatment of Non-motor symptoms
Chair : Andreas Puschmann, Ashkan Keyoumars
|Cognition and neuropsychiatry.
Daniel Weintraub (US)
|Specific management of sleep, pain and fatigue: the vital 3:
Cristian Falup-Pecurariu (Romania)
Alexander Storch (Germany)
|Advanced infusion therapies and specific NMS:
Per Odin (Sweden)
|Differences in NM effect profiles of advanced therapies: relevance for therapy decisions.
Lars Timmermann (Germany)
|1830 - 1845||Coffee|
|1845 - 1900||
Industry symposium Ever Pharma: The efficacy of apomorphine – a non-motoric perspective.
Friday 17, September, 2021
|0830-1000||Session 4: The future and unmet needs
Chair: Peter Jenner, Angela Cenci Nilsson
|Covid 19 , non motor symptoms and Parkinsonism:
Elena Moro (France)
|NMS and new molecules:
Angelo Antonini (Italy)
|NMS and unmet needs:
K Ray Chaudhuri (UK)
|Discussion (15 min)|
|1015 - 1030||Industry symposium Symprove: Microbiome and Probiotics in PD.
Lynne Barker (UK)
|1030 - 1045||Summing up
|1600||Opening of the main MDS meeting